Biote Q2 FY26 net loss widens to $7.4 million; revenue drops 9.5% to $44.2 million
BTMD•Q2 FY26 results
- Biote posted a GAAP net loss of $7.4 million, or $(0.23) a share, versus net income of $3.9 million, or $0.10, a year earlier.
- Revenue fell 9.5% to $44.2 million, with procedure revenue down 13.9% to $30.3 million on recall impacts.
- Gross margin narrowed 6.2 percentage points to 65.4%, reflecting higher replacement-product costs and reduced manufacturing efficiencies tied to the recall.
- Non-GAAP adjusted EBITDA slid to $5.6 million from $15.2 million, cutting margin to 12.6% from 31.1%.
Full-year guidance
- Full-year guidance was revised to revenue above $175 million and adjusted EBITDA above $25 million.
- Sequential procedure-revenue improvement is expected in Q3 and Q4.
